PDCD1 and cervical cancer: On the established clinical benefit of PD-1/PD-L1 inhibitors in cervical cancer, the Food and Drug Administration (FDA) has approved pembrolizumab for patients with recurrent or metastatic cervical cancer with disease progression during or after chemotherapy.